
The Children's Investment Fund (TCI)
The Children's Investment Fund (TCI) is an activist London based hedge fund founded by Chris Hohn in 2003. TCI derives its name from a foundation called The Children's Investment Fund Foundation (CIFF) run by Hohn's wife, Jamie Cooper-Hohn. A portion of TCI's profits go to The Children's Investment Fund Foundation making it one of Great Britain's largest charities.
TCI aims to bring a long-term and owner-oriented investing philosophy to the public markets. The firm only takes capital from investors that will commit for multi-year periods. TCI uses a fundamental approach to identify attractive investments and seeks to maintain a constructive, open dialogue with management teams and boards of the companies in which it invests. However, TCI will take active roles if it feels the board and management are not acting in the best interests of the shareholders.
After management at the publicly traded German stock exchange, the Deutsche Borse, ignored the shareholders requests to vote on the proposed acquisition of the London Stock Exchange (LSE) was ignored, TCI successfully fought for board and management change. Afterwards, Deutsche Borse increased in value by 400%.
Intra-Cellular Therapies (ITCI) is a Bright Spot in a Dark Earnings Season, Jefferies Reiterates Buy
View Older Stories
-
Intra-Cellular Therapies (ITCI) Granted FDA Approval of New Dosage Strengths for CAPLYTA
-
Worksport Ltd (WKSP) Gains on Deal with Hyundai America Technical Center
-
Intra-Cellular Therapies (ITCI) Appoints E. Rene Salas to its Board
-
UPDATE: Piper Sandler Downgrades FTC Solar Inc. (FTCI) to Underweight
-
Needham & Company Reiterates Buy Rating, $65 Price Target on Intra-Cellular Therapies (ITCI)
-
Eli Lilly (LLY) Reports Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
-
Jefferies Starts TCI Express Ltd (TCIEXP:IN) at Buy
-
Needham & Company Reiterates Intra-Cellular Therapies (ITCI) at Buy with $65 PT, Sees Caplyta's Growth Accelerating & Potentially Beating Expectations
-
Ondas Holdings Inc. (ONDS) Reports Q4 Revenue of $0.6M, Net Loss of $7M
-
UPDATE: FTC Solar Inc. (FTCI) PT Raised to $5 but BofA Securities Requires Proof of Margin Rebound to Upgrade
-
FTC Solar Inc. (FTCI) PT Raised to $10 at Cowen
-
Altamira Therapeutics (CYTO) Reports Positive In Vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Omicron Variant
-
FTC Solar, Inc (FTCI) Reaffirms 2022 Financial Outlook
-
Intra-Cellular Therapies (ITCI) PT Raised to $90 at Jefferies
-
Intra-Cellular Therapies (ITCI) PT Raised to $71 at Goldman Sachs
-
Needham & Company Reiterates Intra-Cellular Therapies (ITCI) at Buy, Anticipates Uptick Following Earnings
-
Intra-Cellular Therapies (ITCI) Misses Q4 EPS by 5c
-
Adamis Pharmaceuticals (ADMP) Says Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations
-
Intra-Cellular Therapies (ITCI) PT Raised to $65 at Needham & Company
-
Goldman Sachs Starts Intra-Cellular Therapies (ITCI) at Buy
-
Form 13F-HR LAKE STREET ADVISORS For: Dec 31
-
Form SC 13G/A CANADIAN PACIFIC RAILWAY Filed by: TCI Fund Management Ltd
-
Form SC 13G/A CHARTER COMMUNICATIONS, Filed by: TCI Fund Management Ltd
-
Form SC 13G/A BOSTON PROPERTIES INC Filed by: TCI Fund Management Ltd
-
Form 13F-HR TCI Fund Management Ltd For: Dec 31
-
FTC Solar, Inc (FTCI) Announces Supply Contract for APA Group's 88 MW Australian Solar Project
-
Neurocrine Biosciences (NBIX), Intra-Cellular Therapies (ITCI), and Biohaven Pharmaceutical (BHVN) Are Top Potential Acquisition Targets for Biogen (BIIB) - Mizuho Investor Survey
-
Alliance Data Systems (ADS) Renews Long-Term Agreement with Ulta Beauty
-
Form SC 13D/A CANADIAN NATIONAL RAILWA Filed by: TCI Fund Management Ltd
-
Canadian National Railway (CNI) Announces Appointment of Tracy Robinson as President and CEO
-
Intra-Cellular Therapies' (ITCI) Bipolar Depression Therapy Showing Early Signs of an Acceleration - Jefferies
-
Bell Buckle Holdings, Inc. (BLLB) Confirms Removal of Caveat Emptor Designation
-
Roth Capital Downgrades FTC Solar Inc. (FTCI) to Neutral
-
Form 13F-HR TCI Wealth Advisors, For: Dec 31
-
Intra-Cellular Therapies (ITCI) Prices 9.52M Share Offering at $42/sh
-
Pre-Open Stock Movers 01/04: (ISPC) (BLKB) (NXPI) Higher; (ITCI) (CNM) (AFCG) Lower (more...)
-
GreenPower Motor Co. (GP) Announces Deliveries of 4 EV Star Cab and Chassis to TCI Trucks
-
After-Hours Stock Movers 01/03: (BLKB) (WKEY) (OWL) Higher; (ITCI) (CNM) (AFCG) Lower (more...)
-
Intra-Cellular Therapies (ITCI) Announces Proposed Stock Offering
-
Eli Lilly's (LLY) lebrikizumab Demonstrated Significant Skin Improvement and Itch Relief when Combined with Topical Corticosteroids in People with Atopic Dermatitis in Third Phase 3 Study
-
Intra-Cellular Therapies (ITCI) PT Raised to $62 at Cantor Fitzgerald on FDA Approval
-
Intra-Cellular Therapies (ITCI) PT Raised to $88 at Canaccord Genuity Following FDA Approval
-
Increasing unusual call option volume: ECH GRTX ITCI ARDX ICPT
-
Intra-Cellular Therapies (ITCI) PT Raised to $59 at Needham & Company; Sees >$800M in Caplyta Sales by 2026
-
Intra-Cellular Therapies (ITCI) PT Raised to $85 at Jefferies Following FDA Approval
-
Intra-Cellular Therapies (ITCI) Announces U.S. FDA Approval of CAPLYTA for Treatment of Bipolar Depression in Adults
-
Increasing unusual option volume: BBIO ARMK ITCI GRTX CRNT
-
Increasing unusual call option volume: BBIO ITCI CRNT SIX BEKE JBL
-
Form D TCI Acquisition Company,
-
Needham & Company Previews Intra-Cellular Therapies (ITCI) Dec. 17th PDUFA for Caplyta